A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas.

Slides:

Advertisements

Similar presentations

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.

Advertisements

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

Early Stem Cell Transplantation for Refractory Acute Leukemia after Salvage Therapy with High-Dose Etoposide and Cyclophosphamide Asha Johny, Kevin W.

Comparison of Survival in Patients with T Cell Lymphoma after Autologous and Allogeneic Stem Cell Transplantation as a Frontline Strategy or in Relapsed.

The Prognostic Value Of Dynamic Monitoring C-Reactive Protein (CRP) Serum Levels In NK/T-Cell Lymphoma by Bing Bai, Qi-chun Cai, Xiao-Xiao Wang, Qingqing.

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia.

The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma.

Adaptive Immunotherapy with Autologous CD25-Depleted and CD3/CD28-Costimulated T-Cells Enhances Lymphocyte Recovery after Cyclophosphamide - Fludarabine.

by James O. Armitage, and Dan L. Longo

The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk.

Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.

Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.

The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.

Nonmyeloablative conditioning for relapsed follicular lymphoma

Superior Survival after Autologous vs

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

Autologous Transplantation Therapy for Chronic Myelogenous Leukemia

Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,

166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.

The Outcome of Sibling and Unrelated Donor Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia in First Remission Who Were.

Autologous Stem Cell Transplantation with Thiotepa, Busulfan, and Cyclophosphamide (TBC) Conditioning in Patients with CNS Involvement by Non-Hodgkin.

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

Evaluation Of Myeloablative Therapy Followed By Autologous Stem Cell Transplantation In First Remission In Patients With Advanced Stage Follicular Lymphoma.

Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma.

Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:

A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular.

Minimal Identifiable Disease and the Role of Conditioning Intensity in Hematopoietic Cell Transplantation for Myelodysplastic Syndrome and Acute Myelogenous.

Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia Vivian.

Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.

An expanded phase I/II trial of cyclophosphamide, etoposide, and carboplatin plus total body irradiation with autologous marrow or stem cell support for.

A Phase I/II Study of Chemotherapy Followed by Donor Lymphocyte Infusion plus Interleukin-2 for Relapsed Acute Leukemia after Allogeneic Hematopoietic.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

A Comparison of Cyclophosphamide and Total Body Irradiation with Etoposide and Total Body Irradiation as Conditioning Regimens for Patients Undergoing.

The International Prognostic Index Assessed at Relapse Predicts Outcomes of Autologous Transplantation for Diffuse Large-Cell Non-Hodgkin’s Lymphoma in.

Phase II Trial of 131-Iodine Tositumomab with High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Diffuse Large B Cell Lymphoma

NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report.

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Transplantation Conditioning Regimens and Outcomes after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents with Acute Lymphoblastic.

Is There a Role for Autologous Stem Cell Transplantation for Patients with Acute Myelogenous Leukemia? A Retrospective Analysis Nicolas Novitzky, Valda.

Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I- Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients.

Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in.

Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting.

Kamal Kant Singh Abbi, Junting Zheng, Sean M

High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma Lisa Y. Law,

Elevated Ferritin Is Associated with Relapse after Autologous Hematopoietic Stem Cell Transplantation for Lymphoma Anuj Mahindra, Brian Bolwell, Ronald.

Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplantation in Children, Adolescents, and Young Adults with.

Pretransplantation Therapy with Azacitidine vs Induction Chemotherapy and Posttransplantation Outcome in Patients with MDS Aaron T. Gerds, Ted A. Gooley,

Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation Mohammed M. Elayan, Justin G.

The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age Lujia Dong,

Pretargeted Radioimmunotherapy Using an Anti-CD45 Antibody-Streptavidin Conjugate and Radiolabeled DOTA-Biotin in Patients with High-Risk Acute Leukemia.

HLA-Allele Matched Unrelated Donors Compared to HLA-Matched Sibling Donors: Role of Cell Source and Disease Risk Category Ann Woolfrey, Stephanie J.

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Bridge to transplant following Bv+Bs regimen.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Paclitaxel-Based High-Dose Chemotherapy with Autologous Stem Cell Rescue for Relapsed Germ Cell Cancer Kim A. Margolin, James H. Doroshow, Paul Frankel,

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Frédéric Baron, Effie W. Petersdorf, Ted Gooley, Brenda M

Treatment options for relapsed and refractory multiple myeloma

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

An algorithmic approach to FL

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

How I treat early-relapsing follicular lymphoma

Patient Tregs express normal levels of suppression.

by Lapo Alinari, and Kristie A. Blum

by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal

Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and.

Presentation transcript:

A phase I/II trial of iodine-131–tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas by Oliver W. Press, Janet F. Eary, Ted Gooley, Ajay K. Gopal, Stephen Liu, Joseph G. Rajendran, David G. Maloney, Stephen Petersdorf, Sharon A. Bush, Lawrence D. Durack, Paul J. Martin, Darrell R. Fisher, Brent Wood, James W. Borrow, Bruce Porter, Justin P. Smith, Dana C. Matthews, Frederick R. Appelbaum, and Irwin D. Bernstein Blood Volume 96(9): November 1, 2000 ©2000 by American Society of Hematology

Overall survival of patients with relapsed B-cell lymphomas with 2 treatments.Fifty-two patients were treated with 131I-tositumomab, etoposide, cyclophosphamide, and autologous stem-cell transplantation (ASCT) (thin line), and 105 patients were treated with... Oliver W. Press et al. Blood 2000;96: ©2000 by American Society of Hematology

Progression-free survival in patients with relapsed B-cell lymphomas.Fifty-two patients were treated with 131I-tositumomab, etoposide, cyclophosphamide, and ASCT (thin line), and 105 patients were treated with external-beam TBI (1.5 Gy twice a day for 4 day... Oliver W. Press et al. Blood 2000;96: ©2000 by American Society of Hematology

Survival analyses according to type of lymphoma.(A) Overall survival in 38 patients with relapsed indolent lymphomas (thin solid line) and 14 patients with relapsed aggressive lymphomas (short dashes) treated with 131I-tositumomab, etoposide, cyclophosphami... Oliver W. Press et al. Blood 2000;96: ©2000 by American Society of Hematology

Landmark analyses of bone marrow and blood.Solid symbols indicate presence of a clonal marker indicative of lymphoma; open symbols indicate absence of clonal markers. Oliver W. Press et al. Blood 2000;96: ©2000 by American Society of Hematology

Landmark analyses in the 42 patients with serial cytogenetic assessments of bone marrow samples.Normal cytogenetic findings, ■; abnormal results, ▪. Oliver W. Press et al. Blood 2000;96: ©2000 by American Society of Hematology